Exousia Has Successfully Renegotiated Its License Agreement
Exousia Pro (OTCPINK:MAJI) has successfully renegotiated its license agreement with Progenicyte of Japan, reducing the licensing fee from 50% to 30% equity position. The agreement grants worldwide licensing rights to Progenicyte's Exosome DNA loading patent and future exosome technologies.
Under the new terms, Exousia Pro will pay Progenicyte a monthly operating fee of $16,667. The patent has been filed in Japan, US, Canada, Europe, and China. Progenicyte will continue developing new exosome uses and devices exclusively licensed to Exousia Pro.
The company views this technology as important for scaling exosome manufacturing, noting that among approximately 10,000 active clinical trials, only 10 currently use exosomes. Exousia Pro aims to demonstrate the technology's potential in Glioblastoma treatment and believes it could compete with the monoclonal antibodies market, which represents over 30% of pharmaceutical sales.
Exousia Pro (OTCPINK:MAJI) ha rinegoziato con successo il suo contratto di licenza con Progenicyte del Giappone, riducendo la commissione di licenza dalla posizione patrimoniale del 50% al 30%. L'accordo concede diritti di licenza mondiali sul brevetto per il caricamento di DNA negli esosomi di Progenicyte e sulle future tecnologie degli esosomi.
Secondo i nuovi termini, Exousia Pro pagherà a Progenicyte una commissione operativa mensile di $16,667. Il brevetto è stato depositato in Giappone, negli Stati Uniti, in Canada, in Europa e in Cina. Progenicyte continuerà a sviluppare nuovi utilizzi e dispositivi per esosomi, esclusivamente concessi in licenza a Exousia Pro.
L'azienda considera questa tecnologia come fondamentale per scalare la produzione di esosomi, notando che tra circa 10.000 trial clinici attivi, solo 10 attualmente utilizzano esosomi. Exousia Pro punta a dimostrare il potenziale della tecnologia nel trattamento del Glioblastoma e crede che possa competere con il mercato degli anticorpi monoclonali, che rappresenta oltre il 30% delle vendite farmaceutiche.
Exousia Pro (OTCPINK:MAJI) ha renegociado con éxito su acuerdo de licencia con Progenicyte de Japón, reduciendo la tarifa de licencia de una posición de capital del 50% al 30%. El acuerdo otorga derechos de licencia mundial sobre la patente de carga de ADN de exosomas de Progenicyte y futuras tecnologías de exosomas.
Bajo los nuevos términos, Exousia Pro pagará a Progenicyte una tarifa operativa mensual de $16,667. La patente ha sido registrada en Japón, EE. UU., Canadá, Europa y China. Progenicyte continuará desarrollando nuevos usos y dispositivos de exosomas, exclusivamente licenciados a Exousia Pro.
La empresa considera que esta tecnología es importante para escalar la producción de exosomas, señalando que entre aproximadamente 10,000 ensayos clínicos activos, solo 10 utilizan actualmente exosomas. Exousia Pro tiene como objetivo demostrar el potencial de la tecnología en el tratamiento del Glioblastoma y cree que podría competir con el mercado de anticuerpos monoclonales, que representa más del 30% de las ventas farmacéuticas.
Exousia Pro (OTCPINK:MAJI)는 일본의 Progenicyte와의 라이센스 계약을 성공적으로 재협상하여 라이센스 비용을 50%에서 30% 지분으로 줄였습니다. 이 계약은 Progenicyte의 엑소좀 DNA 로딩 특허 및 미래의 엑소좀 기술에 대한 전 세계 라이센스 권리를 부여합니다.
새로운 조건에 따라 Exousia Pro는 Progenicyte에 월 운영비로 $16,667를 지불합니다. 이 특허는 일본, 미국, 캐나다, 유럽 및 중국에 출원되었습니다. Progenicyte는 Exousia Pro에 독점적으로 라이센스된 새로운 엑소좀 사용 및 장치를 계속 개발할 것입니다.
회사는 이 기술이 엑소좀 제조의 확장에 중요하다고 보고하며, 약 10,000개의 활성 임상 시험 중 현재 10개만이 엑소좀을 사용하고 있다고 언급했습니다. Exousia Pro는 이 기술의 잠재력을 교모세포종 치료에 입증하고, 이 기술이 제약 판매의 30% 이상을 차지하는 단클론 항체 시장과 경쟁할 수 있을 것이라고 믿고 있습니다.
Exousia Pro (OTCPINK:MAJI) a renégocié avec succès son contrat de licence avec Progenicyte du Japon, réduisant les frais de licence de 50 % à 30 % de part d'équité. L'accord accorde des droits de licence mondiaux sur le brevet de chargement d'ADN des exosomes de Progenicyte et sur les futures technologies d'exosomes.
Selon les nouveaux termes, Exousia Pro versera à Progenicyte des frais d'exploitation mensuels de 16 667 $. Le brevet a été déposé au Japon, aux États-Unis, au Canada, en Europe et en Chine. Progenicyte continuera à développer de nouvelles utilisations et dispositifs d'exosomes, exclusivement licenciés à Exousia Pro.
L'entreprise considère cette technologie comme essentielle pour l'échelle de production des exosomes, notant que parmi environ 10 000 essais cliniques actifs, seuls 10 utilisent actuellement des exosomes. Exousia Pro vise à démontrer le potentiel de la technologie dans le traitement du Glioblastome et croit qu'elle pourrait rivaliser avec le marché des anticorps monoclonaux, qui représente plus de 30 % des ventes pharmaceutiques.
Exousia Pro (OTCPINK:MAJI) hat erfolgreich seinen Lizenzvertrag mit Progenicyte aus Japan neu verhandelt und die Lizenzgebühr von 50% auf 30% Eigenkapitalanteil reduziert. Die Vereinbarung gewährt weltweite Lizenzrechte an Progenicytes Patent zur DNA-Beladung von Exosomen und zukünftigen Exosomtechnologien.
Unter den neuen Bedingungen wird Exousia Pro Progenicyte eine monatliche Betriebsgebühr von 16.667 $ zahlen. Das Patent wurde in Japan, den USA, Kanada, Europa und China eingereicht. Progenicyte wird weiterhin neue Anwendungen und Geräte für Exosomen entwickeln, die exklusiv an Exousia Pro lizenziert sind.
Das Unternehmen betrachtet diese Technologie als wichtig für die Skalierung der Exosomenproduktion und weist darauf hin, dass von etwa 10.000 aktiven klinischen Studien nur 10 derzeit Exosomen verwenden. Exousia Pro zielt darauf ab, das Potenzial der Technologie in der Behandlung von Glioblastomen zu demonstrieren und glaubt, dass sie mit dem Markt für monoklonale Antikörper konkurrieren könnte, der über 30% des Pharmaverkaufs ausmacht.
- Reduced licensing fee from 50% to 30% equity position, decreasing shareholder dilution
- Secured worldwide rights to valuable Exosome DNA loading patent and future technologies
- Patent protection filed in major markets (US, Canada, Europe, China, Japan)
- Technology addresses key bottleneck in exosome manufacturing scalability
- Potential to compete in monoclonal antibodies market (>30% of pharmaceutical sales)
- Monthly operating fee obligation of $16,667 to Progenicyte
- Still requires 30% equity position for licensing rights
- No proven clinical success yet - technology remains in development phase
ORLANDO, FL / ACCESS Newswire / March 18, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is pleased to announce it has successfully renegotiated the license agreement it acquired with Progenicyte of Japan.
Exousia Pro has reduced its licensing fee from
The initial agreement executed between Exousia AI and Progenicyte called for Progenicyte to receive
"The reduction in our license fee further demonstrates our commitment to building a strong company without sacrificing our shareholders with unnecessary dilution," stated Mike Sheikh, CEO of Exousia Pro, Inc. "This is a very valuable license because the loading of an exosome represents a major bottleneck in the scaling of exosome manufacturing. There are only 10 clinical trials using exosomes and close to 10,000 active clinical trials, which means there is a lot of growth potential. We now hold the keys to the widespread adoption of targeted exosome loading. Once we demonstrate our first case study in Glioblastoma, we believe the number of applications could mushroom and eventually exceed the existing market of monoclonal antibodies in the long term. Over
About us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
What are the new terms of MAJI's license agreement with Progenicyte?
In which countries has MAJI filed the Exosome DNA loading patent?
How many clinical trials currently use exosomes compared to total active trials?
What is MAJI's first target application for their exosome technology?
How does the renegotiated agreement benefit MAJI shareholders?
